Pneumococcal 23-polyvalent vaccine Pregnancy and Breastfeeding Warnings
Brand names: Pneumovax 23
Medically reviewed by Drugs.com. Last updated on Oct 2, 2023.
Pneumococcal 23-polyvalent vaccine Pregnancy Warnings
Safety has not been established during pregnancy; use only if clearly needed.
AU TGA pregnancy category: B2
US FDA pregnancy category: C
Animal studies have not been performed. There are no controlled data in human pregnancy.
AU TGA pregnancy category B2: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals are inadequate or may be lacking, but available data show no evidence of an increased occurrence of fetal damage.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Pneumococcal 23-polyvalent vaccine Breastfeeding Warnings
This drug should be used only if clearly needed.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
See also
References for pregnancy information
- Product Information. Pneumovax 23 (pneumococcal 23-polyvalent vaccine). Merck & Co., Inc. 2022.
- Cerner Multum, Inc. UK Summary of Product Characteristics.
- Cerner Multum, Inc. Australian Product Information.
References for breastfeeding information
- Product Information. Pneumovax 23 (pneumococcal 23-polyvalent vaccine). Merck & Co., Inc. 2022.
- Cerner Multum, Inc. UK Summary of Product Characteristics.
- Cerner Multum, Inc. Australian Product Information.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
